CRISPR-Cas9 Guide RNA Optimization for Specificity and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies, such as designer zinc fingers and TALEs, are not scalable, affordable, or easily adaptable for targeting multiple positions within the eukaryotic genome, limiting their applicability in advanced biological and medical applications.
Innovation Solution
The CRISPR-Cas system, which uses a single Cas enzyme programmed by a short RNA molecule to target specific DNA sequences, is optimized for improved target specificity and efficiency by using guide RNAs of optimal length, chimeric Cas9 enzymes, and mutations to reduce toxicity and off-target modifications, enabling versatile applications in gene editing and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If designer zinc fingers or TALEs are used for genome editing, then target specificity can be achieved, but scalability and ease of targeting multiple positions is limited
Solution Approach 1:
The patent employs a universal CRISPR-Cas9 system where a single Cas9 enzyme can be programmed to target multiple different genomic positions by simply changing the guide RNA sequence. This eliminates the need to design and construct different protein complexes for each target site, as required by zinc finger or TALE approaches. The guide RNA acts as a programmable adapter that directs the Cas9 enzyme to any desired location in the genome, providing both high specificity and unlimited versatility.
Solution Approach 2:
The patent uses guide RNA molecules that can be easily synthesized and replicated to direct the Cas9 enzyme to different target sites. Instead of creating new protein complexes for each target, the system copies the same Cas9 enzyme multiple times and programs each copy with a different guide RNA sequence. This dramatically simplifies the process of targeting multiple positions in the genome.
2Ease of operation
If CRISPR-Cas system is used for genome editing, then scalability and ease of operation improve, but off-target modifications and toxicity may increase
Solution Approach 1:
The patent optimizes the length and sequence composition of guide RNAs to enhance specificity. By carefully controlling the guide RNA parameters (length, GC content, sequence composition), the system achieves high target specificity while minimizing off-target effects. The patent also uses truncated guide RNAs (shorter than the standard 20 nucleotides) in some embodiments, which have been shown to reduce off-target binding while maintaining on-target activity.
Solution Approach 2:
The patent introduces site-specific modifications to the Cas9 enzyme through mutagenesis, creating variants with altered properties. Specific amino acid substitutions in the Cas9 protein are designed to reduce off-target cleavage activity while preserving on-target efficiency. This local optimization of the enzyme's properties allows the system to maintain ease of operation while reducing harmful off-target effects.
3Power
If wild-type Cas9 enzyme is used, then catalytic activity is high, but toxicity and off-target effects increase
Solution Approach 1:
The patent uses point mutations in the Cas9 enzyme to modulate its catalytic activity. By changing specific amino acid residues in the catalytic domains (such as the HNH and RuvC domains), the patent creates nickase variants that cleave only one strand of DNA or dead Cas9 variants that bind but do not cleave. These parameter changes in enzymatic activity allow the system to reduce toxicity and off-target effects while maintaining sufficient catalytic function for therapeutic applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies genome editing, enhances specificity, and reduces toxicity, making it more scalable and applicable for diverse biological and medical applications, including gene therapy and drug discovery, by allowing precise modification of genetic elements across the eukaryotic genome.
Implementation Method 1
a guide sequence hybridized to a target sequence within the target polynucleotide
Implementation Method 2
The CRISPR complex of the invention provides an effective means for modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide
Data Source
AI summary
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.